Company news
Vir Biotechnology, Inc. news in 2022
Vir Biotechnology, Inc.'s news releases, calls and decks from 2022, newest first.
Vir Biotechnology Achieves Target Enrollment for Groundbreaking Phase 2 PENINSULA Trial Evaluating VIR-2482 for Prevention of Seasonal Influenza A
December 20, 2022
Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™
November 15, 2022
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection
November 5, 2022
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2022 Financial Results
November 2, 2022
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2022
October 30, 2022
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2022 Financial Results on November 3, 2022
October 27, 2022
Vir Biotechnology Announces First Patient Dosed in Groundbreaking Phase 2 Trial of VIR-2482 for Antibody Prophylaxis of Influenza A
October 17, 2022
Vir Biotechnology to Participate in the H. C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference
October 10, 2022
Vir Biotechnology Awarded U.S. Government Contract to Support Pandemic Preparedness for Influenza and Other Infectious Disease Threats
October 3, 2022
Vir Biotechnology Announces First Patient Dosed in the Phase 2 SOLSTICE Trial Evaluating VIR-2218 and VIR-3434 for the Treatment of Chronic Hepatitis D Virus Infection
September 21, 2022
Vir Biotechnology to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
September 5, 2022
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2022 Financial Results
August 8, 2022
Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2022 Financial Results on August 4, 2022
July 20, 2022
Vir Biotechnology Announces Transition of Chief Scientific Officer
July 13, 2022
Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program
June 24, 2022
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at the International Liver Congress™ 2022
June 7, 2022
Vir Biotechnology Reminds Stockholders of 2022 Annual General Meeting Details
May 17, 2022
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 4, 2022
Vir Biotechnology Announces New Data From the MARCH Hepatitis B Trial, Unveils New Hepatitis D Clinical Program and Highlights Broad Hepatitis Portfolio at Virtual Hepatitis Portfolio R&D Day
April 26, 2022
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2022 Financial Results on May 5, 2022
April 20, 2022
Vir Biotechnology to Host a Virtual Hepatitis Portfolio R&D Day
April 12, 2022
Vir Biotechnology Scientists Named Winners of the BARDA and HHS-Sponsored Pediatric COVID-19 Data Challenge
April 5, 2022
Vir Biotechnology to Participate in the 21st Annual Needham Healthcare Conference
April 3, 2022
Vir Biotechnology to Participate in the 42nd Annual Cowen Healthcare Conference
March 1, 2022
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
February 23, 2022
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022
February 9, 2022
Data Suggest Sotrovimab Retains Neutralizing Activity Against Omicron Subvariant BA.2
February 8, 2022
Vir Biotechnology Appoints Johanna Friedl-Naderer as Executive Vice President and Chief Business Officer, Global
February 7, 2022
Vir Biotechnology Launches New Antibody Research Initiative Aimed at a Functional Cure for HIV and Prevention of Malaria
January 12, 2022
GSK and Vir Submit Emergency Use Authorization Application to FDA for Intramuscular Administration of Sotrovimab for the Early Treatment of COVID-19
January 12, 2022
GSK and Vir Biotechnology Announce United States Government Agreement to Purchase Additional Supply of Sotrovimab, Authorized for the Early Treatment of COVID-19
January 10, 2022
Vir Biotechnology to Present at 40th Annual J.P. Morgan Healthcare Conference
January 3, 2022
Decks in 2022
- Corporate Update (February 2022)
Corporate update · 20 slides · Feb 24, 2022